Published in Int J Endocrinol on September 02, 2014
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care (1997) 49.11
Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med (2005) 28.21
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med (2000) 18.04
High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med (1977) 15.39
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation (1989) 9.97
Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev (2006) 3.26
Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care (2002) 3.00
Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum (2006) 2.90
Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. Circulation (1997) 2.74
Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta (1987) 2.70
Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol (2005) 2.61
Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes (2003) 2.40
Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia (2003) 2.38
Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am Heart J (2006) 2.22
High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol (2004) 2.00
C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol (2003) 1.99
HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis (2002) 1.87
Mechanisms of disease: proatherogenic HDL--an evolving field. Nat Clin Pract Endocrinol Metab (2006) 1.83
Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux. J Lipid Res (2005) 1.83
Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Diabetes Care (2007) 1.80
Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med (2011) 1.75
Insulin resistance and the relationship of a dyslipidemia to coronary heart disease: the Framingham Heart Study. Arterioscler Thromb Vasc Biol (2011) 1.66
The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol (2007) 1.63
Risk factors that attenuate the female coronary disease advantage. Arch Intern Med (1995) 1.59
Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations. Biochim Biophys Acta (1993) 1.57
Metabolic and functional relevance of HDL subspecies. Curr Opin Lipidol (2011) 1.52
Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol (2000) 1.49
Role of LCAT in HDL remodeling: investigation of LCAT deficiency states. J Lipid Res (2006) 1.47
An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb (2009) 1.44
Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol (2005) 1.43
The Münster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J (1998) 1.31
Cholesterol efflux from cultured adipose cells is mediated by LpAI particles but not by LpAI:AII particles. Biochem Biophys Res Commun (1987) 1.30
HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis. Atherosclerosis (2009) 1.26
Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease. EMBO Mol Med (2012) 1.26
Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis (2011) 1.24
The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochim Biophys Acta (2011) 1.23
Serum amyloid A changes high density lipoprotein's cellular affinity. A clue to serum amyloid A's principal function. Lab Invest (1992) 1.22
Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease. J Lipid Res (1991) 1.21
A biochemical fluorometric method for assessing the oxidative properties of HDL. J Lipid Res (2011) 1.17
Inflammatory markers in women with a recent history of gestational diabetes mellitus. J Endocrinol Invest (2005) 1.09
The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol (2013) 1.07
Diabetes mellitus and cardiovascular disease in women. Arch Intern Med (1998) 1.06
Synergy between adiposity, insulin resistance, metabolic risk factors, and inflammation in adolescents. Diabetes Care (2009) 1.06
Should low high-density lipoprotein cholesterol (HDL-C) be treated? Best Pract Res Clin Endocrinol Metab (2013) 1.05
C-reactive protein: risk factor, biomarker and/or therapeutic target? Can J Cardiol (2010) 1.05
Friend Turns Foe: Transformation of Anti-Inflammatory HDL to Proinflammatory HDL during Acute-Phase Response. Cholesterol (2010) 1.02
Physiological role and clinical relevance of high-density lipoprotein subclasses. Curr Opin Lipidol (1994) 1.01
Association of C-reactive protein with surrogate measures of insulin resistance among nondiabetic US from National Health and Nutrition Examination Survey 1999-2002. Clin Chem (2007) 1.00
Stimulation of cell surface F1-ATPase activity by apolipoprotein A-I inhibits endothelial cell apoptosis and promotes proliferation. Arterioscler Thromb Vasc Biol (2009) 0.99
Interleukin-6 serum levels and genotypes influence the risk for myocardial infarction. Atherosclerosis (2003) 0.96
Influence of menopause and cholesteryl ester transfer protein (CETP) TaqIB polymorphism on lipid profile and HDL subpopulations distribution in women with and without type 2 diabetes. Atherosclerosis (2009) 0.93
Impact of inflammatory biomarkers on relation of high density lipoprotein-cholesterol with incident coronary heart disease: cardiovascular Health Study. Atherosclerosis (2013) 0.91
Apolipoproteins as the basis for heterogeneity in high-density lipoprotein2 and high-density lipoprotein3. Studies by isoelectric focusing on agarose films. Eur J Biochem (1984) 0.89
Sex difference in the association of metabolic syndrome with high sensitivity C-reactive protein in a Taiwanese population. BMC Public Health (2010) 0.85
The emerging anti-inflammatory role of HDL-cholesterol, illustrated in cardiovascular disease free population; the ATTICA study. Int J Cardiol (2006) 0.83
HDL in atherosclerosis: actor or bystander? Atheroscler Suppl (2003) 0.82
Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction. Am J Cardiol (2007) 0.78
Ischemic heart disease in women and the role of hormone therapy. Int J Cardiol (2004) 0.77
Fracture Risk in Type 2 Diabetes: Current Perspectives and Gender Differences. Int J Endocrinol (2016) 1.09
Corrigendum to "Fracture Risk in Type 2 Diabetes: Current Perspectives and Gender Differences". Int J Endocrinol (2017) 0.75
Sex-Specific Impact of Different Obesity/Metabolic Phenotypes on Long-Term Cardiovascular Outcomes in Acute Coronary Syndrome Patients. Biomedicines (2022) 0.75